High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy

Hepatology

Volumn 50, Issue 6, 2009, Pages 1765-1772

  Fan, Xiaofeng ^a,b   Mao, Qing ^c,d   Zhou, Donghui ^a,e   Lu, Yang ^a   Xing, Jianwei ^a   Xu, Yanjuan ^a   Ray, Stuart C ^c   Di Bisceglie, Adrian M ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saint Louis University   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UNINDEXED SEQUENCE; VIROLOGY; VIRUS LOAD; VIRUS STRAIN;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; VIRAL LOAD;

EID: 73149108234     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23290     Document Type: Article

References (45)

1. National Institutes of Health. NIH Consensus Development Conference Statement: management of hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S3-S20.
2. Feld, JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-972.
3. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007;20:23-38.
4. Upchurch DA, Shankarappa R, Mullins JI. Position and degree of mismatches and the mobility of DNA heteroduplexes. Nucleic Acids Res 2000;28:E69.
5. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepatitis 2007;14:721-729.
6. Higgins DG, Sharp PM. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene 1988;73:237-244.
7. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999; 41:95-98.
8. Clauset A, Shalizi CR, Newman MEJ. Power-law distributions in empirical data. 2007; http://arxiv.org/abs/0706.1062.
9. Di Bisceglie AM, Fan X, Chambers T, Strinko J. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. J Med Virol 2006;78:446-451.
10. Ross RS, Viazov S, Roggendorf M. Genotyping of hepatitis C virus isolates by a new line probe assay using sequence information from both the 5' untranslated and the core regions. J Virol Methods 2007;143:153-160.
11. Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, Longo R, et al. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 2004;40:831-836.
12. Shan-Lu Liu SL, Rodrigo AG, Shankarappa R, Learn GH, Hsu L, Davidov O, et al. HIV quasispecies and resampling. Science 1996;273:413-417.
13. Fan X, Solomon H, Poulos JE, Neuschwander-Tetri BA, Di Bisceglie AM. Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Am J Gastroenterol 1999;94:1347-1354.
14. Fan X, Lyra AC, Tan D, Xu Y, Di Bisceglie AM. Differential amplication of hypervariable region 1 of hepatitis C virus by partially mismatched primers. Biochem Biophys Res Commun 2001;284:694-697.
15. Torres-Puente M, Bracho MA, Jimenez N, Garcia-Robles I, Moya A, Gonzalez-Candelas F. Sampling and repeatability in the evaluation of hepatitis C virus genetic variability. J Gen Virol 1003;84:2343-2350.
16. Ferenci P, Fried M, Shiffman M, Smith C, Marinos G, Gonçales F, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005;43:425-433.
17. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharm Therap 2006;23:1043-1054.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
19. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-1023.
20. Nei M. Phylogenetic analysis in molecular evolutionary genetics. Annu Rev Genet 1996;30:371-403.
21. Mondelli MU, Cerino A, Meola A, Nicosia A. Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. J Biosci 2003;28:305-310.
22. Mondelli MU, Cerino A, Segagni L, Meola A, Cividini A, Silini E, et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antivir Res 2001;52:153-159.
23. Bak P. How Nature Works: The Science of Self-organized Criticality. New York: Springer; 1999:1-31.
24. Gonzalez-Peralta RP, Qian K, She JY, Davis GL, Ohno T, Mizokami M, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 1996;49:242-247.
25. Hino K, Yamaguchi Y, Fujiwara D, Katoh Y, Korenaga M, Okazaki M, et al. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat 2000;7:36-42.
26. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. HEPATOLOGY 1994;20:1121-1130.
27. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment.HEPATOLOGY 1995;22:30-35.
28. Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, et al. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995;108:789-795.
29. Nagasaka A, Hige S, Tsunematsu I, Yoshida J, Sasaki Y, Matsushima T, et al. Changes in hepatitis C virus quasispecies and density populations in patients before and after interferon therapy. J Med Virol 1996;50:214-220.
30. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. HEPATOLOGY 1992;16:619-624.
31. Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. HEPATOLOGY 1996;24:1018-1023.
32. Le Guen B, Squadrito G, Nalpas B, Berthelot P, Pol S, Brechot C. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. HEPATOLOGY 1997;25:1250-1254.
33. Lopez-Labrador FX, Ampurdanes S, Gimenez-Barcons M, Guilera M, Costa J, Jimenez MT, et al. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection.HEPATOLOGY 1999;29:897-903.
34. Nakazawa T, Kato N, Ohkoshi S, Shibuya A, Shimotohno K. Characterization of the 5' noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment. J Hepatol 1994;20:623-629.
35. Sandres K, Dubois M, Pasquier C, Payen JL, Alric L, Duffaut M, et al. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity ofHCVto alpha interferon therapy. J Virol 2000;74:661-668.
36. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005;79:3071-3083.
37. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 2002;99:3081-3086.
38. Sarrazin C, Bruckner M, Herrmann E, Rüster B, Bruch K, Roth WK, et al. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology 2001;289:150-163.
39. Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, Bracho MA, Garcia-Robles I, Wrobel B, et al. Genetic variability in hepatitis C virus and its role in antiviral treatment response. J Viral Hepatitis 2008;15:188-199.
40. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, et al. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis 2006;193:931-940.
41. Domingo E. Quasispecies theory in virology. J Virol 2002;76:463-465.
42. Biebricher CK, Eigen M. What is a quasispecies? Curr Top Microbiol 2006;299:1-31.
43. Bak P, Tang C, Wiesenfeld K. Self-organized criticality. Phys Rev 1998; 38:364-374.
44. Wang WK, Lin SR, Lee CM, King CC, Chang SC. Dengue type 3 virus in plasma is a population of closely related genomes: quasispecies. J Virol 2002;76:4662-4665.
45. Jerzak G, Bernard KA, Kramer LD, Ebel GD. Genetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selection. J Gen Virol 2005;86:2175-2183.